We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| -64.00 | -0.53% | 11,962.00 | 1,022,700 | 15:55:15 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 11,962.00 | 11,964.00 | 12,144.00 | 11,882.00 | 12,070.00 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | USD 45.81B | USD 5.96B | USD 3.8415 | 31.11 | 185.25B |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 15:55:18 | O | 11 | 11,962.00 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 25/4/2024 | 09:18 | ALNC |  TOP NEWS: AstraZeneca upbeat as cancer drugs underpin sales growth |
| 25/4/2024 | 07:00 | UK RNS | AstraZeneca PLC 1st Quarter Results |
| 24/4/2024 | 10:32 | ALNC | Angle shares jump on supplier agreement with with AstraZeneca |
| 16/4/2024 | 11:38 | ALNC | IN THE KNOW: Deutsche ups AstraZeneca as higher payout addresses worry |
| 16/4/2024 | 08:39 | ALNC | AstraZeneca's hails Imfinzi survival data on cancer form |
| 11/4/2024 | 17:42 | ALNC | *AstraZeneca AGM resolutions pass, but 36% vote against remuneration policy |
| 11/4/2024 | 17:30 | UK RNS | AstraZeneca PLC Result of AGM |
| 11/4/2024 | 08:56 | ALNC | TOP NEWS: Astra plans 7% dividend hike for 2024 after no rise in 2023 |
| 11/4/2024 | 07:00 | UK RNS | AstraZeneca PLC AstraZeneca increases 2024 dividend by 7% |
| 08/4/2024 | 08:36 | ALNC | TOP NEWS: AstraZeneca hails neurological data for Ultomiris, Soliris |
Astrazeneca (AZN) Share Charts1 Year Astrazeneca Chart |
|
1 Month Astrazeneca Chart |
Intraday Astrazeneca Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 25/4/2024 | 16:10 | AstraZeneca | 6,022 |
| 25/4/2024 | 08:41 | Alzheimer's can be caught .... It's a transmissible disease | 126 |
| 02/11/2021 | 14:29 | ASTRAZENECA, MSD PROSTATE CANCER DRUG GETS CHINA GREEN LIGHT | 2 |
| 20/9/2021 | 15:45 | INDIA'S COVID DEATH RATE IS 278 PER 1 MILLION..UK'S IS 1876..THINK ABOUT IT | 1 |
| 15/9/2021 | 12:17 | Eu | 2 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 14:55:18 | 11,962.00 | 11 | 1,315.82 | O |
| 14:55:13 | 11,962.00 | 30 | 3,588.60 | AT |
| 14:55:12 | 11,962.00 | 14 | 1,674.68 | AT |
| 14:55:10 | 11,962.98 | 10 | 1,196.30 | O |
| 14:55:09 | 11,960.00 | 70 | 8,372.00 | AT |
| Top Posts |
|---|
Posted at 26/4/2024 09:20 by Astrazeneca Daily Update Astrazeneca Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker AZN. The last closing price for Astrazeneca was 12,026p.Astrazeneca currently has 1,550,189,338 shares in issue. The market capitalisation of Astrazeneca is £185,340,637,251. Astrazeneca has a price to earnings ratio (PE ratio) of 31.12. This morning AZN shares opened at 12,070p |
Posted at 16/4/2024 09:57 by philanderer Deutsche Bank raises AstraZeneca to 'hold' (sell) - price target 10,500 (9,500) penceBarclays raises AstraZeneca price target to 13,000 (12,500) pence - 'overweight' |
Posted at 08/4/2024 15:02 by actomox (Alliance News) - AstraZeneca PLC on Monday said long-term data in generalised myasthenia gravis will underscore the "vital role" of its Ultomiris and Soliris antibodies in the treatment landscape.The Cambridge, England-based pharmaceutical company said Ultomiris and Soliris "can transform" patient outcomes in sufferers of rare neurological diseases. Astra will present data from its rare neurology portfolio at the American Academy of Neurology meeting in Denver, Colorado next week. (And, as usual, the share price declines on good news) |
Posted at 08/4/2024 14:47 by wad collector Really?Found 22 results: Blackhorse23 - 08 Apr 2024 - 11:28:43 - 6011 of 6012 AstraZeneca - AZN Money moved to APH Blackhorse23 - 05 Apr 2024 - 09:16:44 - 6009 of 6012 AstraZeneca - AZN Blackhorse23 - 21 Mar 2024 - 08:47:26 - 6002 of 6012 AstraZeneca - AZN Money moving to APH [LSE] , excellent profitable healthcare company Blackhorse23 - 21 Feb 2024 - 14:26:56 - 5995 of 6012 AstraZeneca - AZN Money moving to APH , excellent growth health care company Blackhorse23 - 12 Feb 2024 - 11:37:36 - 5981 of 6012 AstraZeneca - AZN Money moving to APH Blackhorse23 - 29 Jan 2024 - 15:32:08 - 5957 of 6012 AstraZeneca - AZN Blackhorse23 - 19 Jan 2024 - 11:52:35 - 5956 of 6012 AstraZeneca - AZN Ha ha hxxps://www.alliance Blackhorse23 - 18 Jan 2024 - 14:23:42 - 5954 of 6012 AstraZeneca - AZN Bought some APH today Blackhorse23 - 09 Jan 2024 - 11:01:43 - 5948 of 6012 AstraZeneca - AZN are they buying APH ?? |
Posted at 19/3/2024 08:50 by geckotheglorious Wonder how many Fusion Pharm shareholders were relatively new and benefitted from the 97% premium to 18th March close!Bound to have been plenty of insider dealing stateside, probably in "Options" to leverage the benefit. Under the terms of the definitive agreement, AstraZeneca, through a subsidiary, will acquire all of Fusion's outstanding shares pursuant to a plan of arrangement for a price of $21.00 per share in cash at closing plus a non-transferable contingent value right of $3.00 per share in cash payable upon the achievement of a specified regulatory milestone. The upfront cash portion of the consideration represents a transaction value of approximately $2bn, a 97% premium to Fusion's closing market price of $10.64 on 18th March 2024 and an 85% premium to the 30-day volume-weighted average price (VWAP) of $11.37 before this announcement. |
Posted at 12/2/2024 11:11 by 1knocker Quite a spread of views!It is important to bear in mind what a commentator's price target means: it is not 'current fair value', but (unless otherwise stated) a price which the commentator at present believes will be hit at some time within the following 12 months, and not necessarily sustained thereafter, still less that there will not be further rises /falls from the price at the date on which the target was stated before that figure is hit, if indeed it is hit. |
Posted at 12/2/2024 10:57 by philanderer Stifel cuts AstraZeneca price target to 12,000 (12,550) pence - 'buy'Barclays cuts AstraZeneca price target to 12,500 (13,500) pence - 'overweigh UBS cuts AstraZeneca price target to 9,900 (10,700) pence - 'sell' |
Posted at 08/2/2024 16:34 by 1knocker AZN is still pretty richly priced. I think it should slide a bit more. I may put a limit order in to buy a few more at 93, though that will significantly above my average, currently 58 after a few out and back in round trips a few years back.AZN does not pay much of a dividend, and I see no catalyst to move the price north at present, so in this uncertain market I shall probably put in my order at 90 and be patient. |
Posted at 15/12/2023 15:44 by smcni1968 Hopefully a better year for the share price in 2024. |
Posted at 05/12/2023 17:50 by turvart AZN now well below the 200 & 50 day moving average, the 200 day MA is approx 11000 area so this is a steal IMO with all the future developments in phase 11 & 111 trials. One aspect I also like is the fact AZN do not stand still and get complacent the company is always striving to get bigger and make regular acquisitions.AZN was my very first stock I purchased when I was a complete newbie back in 2001 and I paid £17.50 a share back then, look at the growth of this immense stock of which I'm sure will get to £130 by the end of 2024 IMO, AZN was in my portfolio in 2001 at 1750 and still are and has been my best performing stock, just wished I'd have bought more and left them alone re-investing the dividends along the way. Strong buy IMO. |
Posted at 05/7/2023 10:06 by philanderer Berenberg lowers AstraZeneca target priceA lung cancer treatment from AstraZeneca (AZN) failed to meet high investor expectations but the share price drop is ‘overdone̵ Analyst Luisa Hector reiterated her ‘buy’ recommendation but lowered her target price slightly from £135 to £133 on the Citywire Elite Companies AAA-rated stock, which rose 2.2%, or 228p, to £106.02 on Tuesday. The pharmaceutical giant, along with its partner Daiichi Sankyo, announced positive progression-free survival headline data for their lung cancer treatment. ‘The absence of more positive language in the press release, such as “clinically meaningful”, and the occurrence of some fatal interstitial lung disease events missed high investor expectations, resulting in AstraZeneca’s share price falling by 8%,’ said Hector. She said the future of the drug relies on further testing, which is expected in the next six months. ‘We lower our price target to £133… a much smaller reduction than the share price move of 900p. We think the stock reaction is overdone given the overall strength of AstraZeneca’s pipeline,’ she said. citywire.com |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
